Novan Therapeutics Expands Leadership Team With Vice President Of Regulatory Affairs

2/26/2015 11:51:11 AM

Novan Therapeutics, a clinical stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that Kevin Barber, Ph.D., has been appointed to the newly created position of Vice President of Regulatory Affairs, effective immediately. Dr. Barber will direct Novan's regulatory strategy as the primary interface with the FDA and will report directly to Dr. Nathan Stasko, Novan's President.

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.